Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (421-430 of 568) with videos related to

Pageof 57
Sort By:
Journal of Crohn'S & Colitis|March 24, 2020
Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Francisco Mesonero, et al.
Journal of Crohn'S & Colitis|February 8, 2020
Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position PaperGionata Fiorino, Theodore Lytras, Lisa Younge, et al.
Journal of Crohn'S & Colitis|January 17, 2022
Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based SurveyPierre Ellul, Joana Revés, Bárbara Abreu, et al.
Alimentary Pharmacology & Therapeutics|August 21, 2019
Increased risk of thiopurine-related adverse events in elderly patients with IBDMargalida Calafat, Míriam Mañosa, Fiorella Cañete, et al.
Gastroenterologia Y Hepatologia|September 12, 2008
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of responseYago González-Lama, Antonio López-San Román, Ignacio Marín-Jiménez, et al.
Journal of Clinical Medicine|March 25, 2022
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)Olga P Nyssen, Dino Vaira, Ilaria Maria Saracino, et al.
Journal of Crohn'S & Colitis|July 12, 2023
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 StudiesSebastiaan Ten Bokkel Huinink, Doranne Thomassen, Ewout W Steyerberg, et al.
Journal of Gastroenterology and Hepatology|May 1, 2020
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agentsMontserrat Guasch, Fiorella Cañete, Ingrid Ordás, et al.
Journal of Crohn'S & Colitis|April 13, 2017
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised TrialAntonio López-Sanromán, Isabel Vera-Mendoza, Eugeni Domènech, et al.
The Pharmacogenomics Journal|May 3, 2019
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's diseaseAdrià Aterido, Núria Palau, Eugeni Domènech, et al.
Pageof 57

Showing results (421-430 of 568) with videos related to

Sort By:
Pageof 57
Journal of Crohn'S & Colitis|March 24, 2020
Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Francisco Mesonero, et al.
Journal of Crohn'S & Colitis|February 8, 2020
Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position PaperGionata Fiorino, Theodore Lytras, Lisa Younge, et al.
Journal of Crohn'S & Colitis|January 17, 2022
Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based SurveyPierre Ellul, Joana Revés, Bárbara Abreu, et al.
Alimentary Pharmacology & Therapeutics|August 21, 2019
Increased risk of thiopurine-related adverse events in elderly patients with IBDMargalida Calafat, Míriam Mañosa, Fiorella Cañete, et al.
Gastroenterologia Y Hepatologia|September 12, 2008
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of responseYago González-Lama, Antonio López-San Román, Ignacio Marín-Jiménez, et al.
Journal of Clinical Medicine|March 25, 2022
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)Olga P Nyssen, Dino Vaira, Ilaria Maria Saracino, et al.
Journal of Crohn'S & Colitis|July 12, 2023
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 StudiesSebastiaan Ten Bokkel Huinink, Doranne Thomassen, Ewout W Steyerberg, et al.
Journal of Gastroenterology and Hepatology|May 1, 2020
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agentsMontserrat Guasch, Fiorella Cañete, Ingrid Ordás, et al.
Journal of Crohn'S & Colitis|April 13, 2017
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised TrialAntonio López-Sanromán, Isabel Vera-Mendoza, Eugeni Domènech, et al.
The Pharmacogenomics Journal|May 3, 2019
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's diseaseAdrià Aterido, Núria Palau, Eugeni Domènech, et al.
Pageof 57